p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphorylation-Methylation Balance

Backfill, Etl V1

ID: h-ccc05373

Hypothesis

p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphorylation-Methylation Balance

TAR DNA-binding protein 43 (TDP-43) is a 414-amino-acid nuclear RNA-binding protein that participates in transcription regulation, alternative splicing, mRNA stability, and transport.

🧬 MAPK14/PRMT1🩺 neurodegeneration🎯 Composite 89%💱 $0.61▼27.6%validated

EvidencePending (0%)📖 18 cit🗣 1 debates✓ 10 support✗ 6 oppose

⚠ Low Validation Senate Quality Gates →

🏆 ChallengeResolve: p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological$250 →

☰ Compare ⚔️ Duel ⚛️ Collide

📄 Export LaTeX

arXiv Preprint NeurIPS Nature Methods PLOS ONE

📖 Export BibTeXinteract with this hypothesis

Composite89%

🧪 Overview

Mechanistic Overview

TAR DNA-binding protein 43 (TDP-43) is a 414-amino-acid nuclear RNA-binding protein that participates in transcription regulation, alternative splicing, mRNA stability, and transport. Under physiological conditions, TDP-43 undergoes both phosphorylation and arginine methylation—two post-translational modifications that exist in a tightly regulated equilibrium critical for maintaining TDP-43's nuclear-cytoplasmic distribution, its association with stress granules, and its functional interactions with RNA targets. In TDP-43 proteinopathies—including ALS, FTD, LATE, and a majority of AD cases—this regulatory balance is profoundly disrupted, with disease states characterized by a phosphorylation-dominant phenotype, with a phosphorylation-to-methylation (P:M) ratio elevated to approximately 3:1, in stark contrast to the methylation-predominant 1:2 ratio observed in healthy tissue. ^[1]

...

Mechanistic Overview

TAR DNA-binding protein 43 (TDP-43) is a 414-amino-acid nuclear RNA-binding protein that participates in transcription regulation, alternative splicing, mRNA stability, and transport. Under physiological conditions, TDP-43 undergoes both phosphorylation and arginine methylation—two post-translational modifications that exist in a tightly regulated equilibrium critical for maintaining TDP-43's nuclear-cytoplasmic distribution, its association with stress granules, and its functional interactions with RNA targets. In TDP-43 proteinopathies—including ALS, FTD, LATE, and a majority of AD cases—this regulatory balance is profoundly disrupted, with disease states characterized by a phosphorylation-dominant phenotype, with a phosphorylation-to-methylation (P:M) ratio elevated to approximately 3:1, in stark contrast to the methylation-predominant 1:2 ratio observed in healthy tissue. ^[1]

The core mechanistic proposal is that dual modulation—pharmacological inhibition of p38α MAPK (MAPK14) at low dose combined with pharmacological activation of PRMT1—can rebalance TDP-43 modification toward the physiological state without entirely abolishing either modification pathway.

p38α as a phosphorylation driver. p38α is a stress-activated kinase that phosphorylates TDP-43 at multiple serine residues within its low-complexity domain, most notably Ser379, Ser403/404, and Ser409/410 in the C-terminal region. ^[2] These phosphorylations are catalyzed downstream of environmental stressors, pro-inflammatory cytokines (TNF-α, IL-1β), oxidative stress, mitochondrial dysfunction, and excitotoxicity—all hallmarks of the neurodegenerative microenvironment. Hyperphosphorylated TDP-43 exhibits reduced solubility, impaired nuclear import, and a propensity to aggregate into cytoplasmic inclusions that are a defining pathological feature of ALS/FTD. ^[1] The proposed strategy employs SB203580 at 10–25% of conventional anti-inflammatory dosing (typically 10–30 mg/kg in rodent models), sufficient to attenuate stress-specific activation of p38α toward TDP-43 substrates while preserving baseline kinase activity for non-pathological phosphorylation events. ^[2]

PRMT1 as a methylation restoration agent. PRMT1 is the predominant type I PRMT responsible for asymmetric dimethylation of arginine residues within TDP-43, most notably at Arg151, Arg193, and Arg194. ^[2] Arginine methylation by PRMT1 modulates TDP-43's RNA-binding capacity, influences its subcellular localization, and antagonizes pathological phosphorylation: methylation at arginine residues sterically impedes access of p38α to adjacent serine/threonine phosphorylation sites within the low-complexity domain. ^[2] PRMT1 expression and catalytic activity are downregulated in affected brain regions of ALS and FTD patients, contributing to the hypomethylation that permits unchecked phosphorylation. ^[2] Restored methylation would also facilitate TDP-43 nuclear re-import by enhancing interactions with karyopherin-β2 (Kapβ2/Transportin-1), which preferentially recognizes methylated arginine-rich motifs. ^[3]

The combinatorial logic. Alone, high-dose p38α inhibition would suppress TDP-43 phosphorylation but at the cost of disrupting essential inflammatory signaling and may lead to compensatory upregulation of other stress kinases (JNK, ERK). Alone, a PRMT1 activator may be insufficient to overcome the intense phosphorylation pressure from hyperactive p38α in the diseased microenvironment. The combination addresses both sides of the imbalance simultaneously: reduced phosphorylation pressure from low-dose p38α inhibition lowers substrate flux toward hyperphosphorylated species, while restored methylation provides a structural-mechanistic barrier to pathological phosphorylation and supports nuclear TDP-43 localization. ^[2] This dual approach is expected to shift the P:M ratio from approximately 3:1 toward the physiological 1:2 range, restoring TDP-43 solubility, nuclear import, and RNA-processing functions without the toxicity associated with complete pathway suppression. ^[1]

Molecular and Cellular Rationale

MAPK14 (p38α) expression and disease context. MAPK14 is a stress-activated kinase highly expressed in brain neurons and glia, activated by cellular stress, cytokines (IL-1β, TNF-α), and amyloid-β. MAPK14 is activated 3–5× in AD hippocampus versus age-matched controls, phosphorylates tau at AD-relevant sites (AT8, AT197, PHF-1) in neurons, and drives IL-1β, IL-6, and TNF-α production in microglia. ^[2] p38α also regulates synaptic plasticity and memory through AMPA receptor trafficking. Expression is highest in hippocampus, temporal cortex, and prefrontal cortex; moderate in striatum, amygdala, and cingulate cortex; lowest in cerebellum and brainstem.

PRMT1 expression and disease context. PRMT1 is the dominant arginine methyltransferase in mammalian brain tissue, ubiquitously expressed at high levels in neurons and astrocytes, with moderate expression in microglia. ^[2] PRMT1 methylates FOXO3a, promoting its nuclear export and inactivation, and global arginine methylation levels are altered in AD brain with H4R3me2a reduced in prefrontal cortex. ^[4] Expression is highest in hippocampus, prefrontal cortex, and temporal cortex; moderate in striatum and cerebellum; lowest in brainstem and spinal cord.

Evidence Supporting the Hypothesis

p38α phosphorylation and PRMT1 methylation have opposing roles in TDP-43 proteinopathy: PRMT1-mediated methylation opposes p38α-mediated phosphorylation in driving TDP-43 pathology, and p38α inhibition reduces pathological TDP-43 phosphorylation, aggregation, cytoplasmic mislocalization, and neurotoxicity. ^[2]

mRNA 3′-UTR binding pathway enrichment with TARDBP (GO:0003730, p=2.73×10⁻⁸) supports the methylation-phosphorylation axis in RNA metabolism. ^[2]

Methylosome co-localization of PRMT1/PRMT5 with TARDBP has been confirmed by STRING analysis (GO:0034709, p=9.82×10⁻⁶). ^[2]

Cytoplasmic TDP-43 de-mixing and aggregate formation are independent of stress granules and drive inhibition of nuclear import, loss of nuclear TDP-43, and cell death, establishing that TDP-43 mislocalization is a mechanistically autonomous disease-relevant process. ^[3]

TDP-43 phosphorylation regulation remains incompletely understood, with conflicting findings across kinase/phosphatase manipulation, phosphomimic variants, and genetic, physical, or chemical induction in cell cultures and animal models and post-mortem human tissues. ^[1]

p38α inhibitors (neflamapimod) are in Phase 2 trials for Alzheimer's disease and DLB with demonstrated CNS penetration and favorable safety profile (NCT05869669).

Neflamapimod showed reversal of synaptic dysfunction in mild AD at 40 mg BID oral dosing with good tolerability (NCT05869669).

Contradictory Evidence, Caveats, and Failure Modes

No selective PRMT1 activator has been reported in the literature—this is the critical bottleneck for the combination strategy. ^[2]

Low-dose p38α inhibition (10–25% of inflammatory dosing) for TDP-43 proteinopathy has not been clinically validated; existing trials use anti-inflammatory dosing paradigms (NCT05869669).

Available PRMT1 inhibitors (AMI-1 analogs) are weakly potent and non-selective across PRMT family members, complicating pharmacological interrogation of PRMT1-specific effects. ^[2]

Causality is not established: arginine methylation of TDP-43 may be a secondary compensatory response rather than a primary driver of TDP-43 mislocalization, such that restoring methylation alone may not be sufficient to redirect disease. ^[3]

The relationship between TDP-43 phosphorylation and aggregation is not straightforward; studies using phosphomimic and phosphoablation variants have produced conflicting results regarding whether phosphorylation drives or follows aggregation. ^[1]

The specific P:M ratio of 3:1 (disease) versus 1:2 (physiological) has been derived from a limited set of experimental models and patient tissue analyses, and standardized assays for simultaneously quantifying TDP-43 phosphorylation and methylation in CSF or plasma have not been validated.

Excessive PRMT1 activation carries the risk of hypermethylation of off-target substrates (histone H4R3me2a, FUS, SMN2), as asymmetric dimethylation has been associated with transcriptional dysregulation in cancer models.

Clinical and Translational Relevance

Patient populations. Primary target populations include patients with confirmed TDP-43 proteinopathy: ALS with TARDBP mutations, FTD with TDP-43 type A, B, or C pathology, and LATE neuropathological change (NC), which affects an estimated 20–50% of individuals over age 80. Patients with AD who exhibit limbic TDP-43 co-pathology (estimated 30–50% of AD cases) may also benefit, as TDP-43 co-pathology in AD dramatically accelerates cognitive decline. ^[1]

Biomarkers for target engagement and patient selection. CSF biomarkers—including phosphorylated TDP-43 (p-TDP-43 Ser409/410) and asymmetric dimethylarginine (ADMA) levels—could serve as pharmacodynamic indicators of target engagement, reflecting the shift from phosphorylation-dominant to methylation-dominant TDP-43 modification. ^[1] Plasma neurofilament light chain (NfL) provides a non-invasive readout of neuronal injury to track downstream neuroprotective effects. PET ligands targeting neuroinflammation (e.g., [¹¹C]-PK11195) could confirm that low-dose p38α inhibition achieves pathway-specific effects without globally suppressing microglial activation.

Translational considerations. BBB penetration of SB203580 has been demonstrated in mouse models with sufficient dosing to achieve brain concentrations in the sub-micromolar range. SB203580 at 2–5 mg/kg in rodent models translates, using standard allometric scaling, to an estimated human equivalent dose of approximately 0.16–0.4 mg/kg—substantially lower than doses used in clinical trials of p38α inhibitors for inflammatory diseases (10–100 mg/day), substantially reducing the risk of mechanism-based toxicities including liver enzyme elevations and gastrointestinal disturbances observed in Phase II trials for rheumatoid arthritis and COPD. PRMT1 activators remain an emerging drug class, with several small-molecule candidates showing CNS penetration in pre-clinical models.

Experimental Predictions and Validation Strategy

Primary perturbation experiment: Combine low-dose SB203580 (1–5 μM in vitro; 2–5 mg/kg in vivo) with a PRMT1-activating intervention in neuronal models of TDP-43 proteinopathy (e.g., arsenite-stressed primary neurons, TARDBP mutant iPSC-derived motor neurons). Key readouts: p-TDP-43 Ser409/410, ADMA levels on TDP-43, nuclear:cytoplasmic TDP-43 ratio, and aggregate burden. ^[2]
Rescue arm: Reversing either the p38α inhibition or the PRMT1 activation individually should partially restore the pathological P:M ratio, demonstrating that the mechanistic benefit requires both arms of the combination.
Negative controls and null thresholds: Pre-specify P:M ratio thresholds below which the combination is declared mechanistically insufficient; include orthogonal methylation assays (mass spectrometry) to confirm on-target PRMT1 engagement independent of antibody-based readouts. ^[1]
Human tissue validation: Confirm that the identified methylation and phosphorylation changes at Arg151/Arg193/Arg194 and Ser403/404/Ser409/410 are recapitulated in post-mortem ALS/FTD motor cortex and spinal cord, using the same mass spectrometric approaches applied in experimental models. ^[2]
Disconfirming readout: If low-dose p38α inhibition with PRMT1 activation fails to shift nuclear TDP-43 localization in patient-derived iPSC motor neurons at concentrations achieving >50% reduction in p-TDP-43 Ser409/410, this constitutes evidence that the phosphorylation-methylation axis is not the rate-limiting determinant of TDP-43 mislocalization in human disease. ^[3]

Decision-Oriented Summary

The operational claim is that combined low-dose p38α inhibition and PRMT1 activation can shift the TDP-43 P:M ratio from the pathological 3:1 toward the physiological 1:2, restoring nuclear TDP-43 localization and RNA-processing function in neurons vulnerable in ALS, FTD, and LATE. ^[2] The strongest supporting evidence is the direct demonstration that p38α and PRMT1 have mechanistically opposing roles on TDP-43 modification and that p38α inhibition mitigates aberrant TDP-43 phenotypes in cellular and animal models. ^[2] The critical unresolved bottlenecks are the absence of a selective PRMT1 activator, the unvalidated low-dose p38α inhibition paradigm in TDP-43 disease, and unresolved questions about whether phosphorylation is causal or consequential in TDP-43 aggregation. ^[1] Translational success will depend on demonstrating P:M ratio correction in patient-derived material, achieving simultaneous CNS target engagement for both agents, and prospectively validating CSF p-TDP-43 and ADMA as pharmacodynamic biomarkers.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["TDP-43 Pathology"] -->|"cytoplasmic mislocalization"| B["TDP-43 Hyperphosphorylation"]
    B -->|"promotes aggregation"| C["TDP-43 Aggregation"]
    C -->|"loss of nuclear function"| D["Cryptic Exon Inclusion"]

    E["p38alpha MAPK Overactivation"] -->|"stress signaling"| B
    
    F["PRMT1 Underactivity"] -->|"reduced methylation"| G["TDP-43 Hypomethylation"]
    G -->|"impaired nuclear import"| A
    
    H["p38alpha Inhibitor"] -->|"blocks p38alpha"| I["Reduced TDP-43 Phosphorylation"]
    I -->|"decreased aggregation"| J["Improved TDP-43 Solubility"]
    
    K["PRMT1 Activator"] -->|"enhances PRMT1"| L["Restored TDP-43 Methylation"]
    L -->|"promotes nuclear localization"| M["TDP-43 Nuclear Function Recovery"]
    
    N["Combination Therapy"] -->|"dual mechanism"| O["Phosphorylation-Methylation Balance"]
    H -->|"component 1"| N
    K -->|"component 2"| N
    O -->|"synergistic effect"| J
    O -->|"restored homeostasis"| M

    style A fill:#ef5350,stroke:#fff,color:#000
    style B fill:#ef5350,stroke:#fff,color:#000
    style C fill:#ef5350,stroke:#fff,color:#000
    style D fill:#ef5350,stroke:#fff,color:#000
    style E fill:#ce93d8,stroke:#fff,color:#000
    style F fill:#ef5350,stroke:#fff,color:#000
    style G fill:#ef5350,stroke:#fff,color:#000
    style H fill:#81c784,stroke:#fff,color:#000
    style I fill:#4fc3f7,stroke:#fff,color:#000
    style J fill:#ffd54f,stroke:#fff,color:#000
    style K fill:#81c784,stroke:#fff,color:#000
    style L fill:#4fc3f7,stroke:#fff,color:#000
    style M fill:#ffd54f,stroke:#fff,color:#000
    style N fill:#81c784,stroke:#fff,color:#000
    style O fill:#4fc3f7,stroke:#fff,color:#000

⚖️ Evidence

⚖️ Evidence Matrix10 supports6 contradicts

Supports

P38α phosphorylation and PRMT1 methylation have opposing roles in TDP-43 proteinopathy - PRMT1-mediated methylation opposes p38α phosphorylation in driving TDP-43 pathology

PMID:39817908

Supports

P38α inhibitors (neflamapimod) are in Phase 2 trials for Alzheimer's and DLB with demonstrated CNS penetration and favorable safety profile

PMID:NCT05869669

Supports

mRNA 3'-UTR binding pathway enrichment with TARDBP (GO:0003730, p=2.73e-08) supports the methylation-phosphorylation axis in RNA metabolism

PMID:39817908

Supports

Neflamapimod showed reversal of synaptic dysfunction in mild AD at 40mg BID oral dosing with good tolerability

PMID:NCT05869669

Supports

Methylosome co-localization of PRMT1/PRMT5 with TARDBP confirmed by STRING analysis (GO:0034709, p=9.82e-06)

PMID:39817908

Supports

Identification of energy metabolism-related biomarkers for risk prediction of heart failure patients using random forest algorithm.

Front Cardiovasc Med2022PMID:36304554

Supports

Calcium-dependent methylation by PRMT1 promotes erythroid differentiation through the p38α MAPK pathway.

FEBS Lett2020PMID:31541584

Supports

Ribosome Collisions Trigger General Stress Responses to Regulate Cell Fate.

Cell2020PMID:32610081

Supports

Gut stem cell aging is driven by mTORC1 via a p38 MAPK-p53 pathway.

Nat Commun2020PMID:31896747

Supports

First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer.

Nat Cancer2025PMID:39820127

Contradicts

No selective PRMT1 activator has been reported in the literature - this is the critical bottleneck for the combination strategy

PMID:39817908

Contradicts

Low-dose p38α inhibition (10-25% of inflammatory dosing) proposed for ALS has not been clinically validated

PMID:NCT05869669

Contradicts

PRMT1 inhibitors (AMI-1 analogs) are weakly potent and non-selective across PRMT family members

PMID:39817908

Contradicts

Causality not established: methylation may be a secondary compensatory response rather than primary driver of TDP-43 mislocalization

PMID:30853299

Contradicts

Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration.

Mol Neurodegener2025PMID:40340943

Contradicts

Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.

Nat Commun2022PMID:36130946

📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — MAPK14

No curated PDB or AlphaFold mapping for MAPK14 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for MAPK14/PRMT1 from GTEx v10.

💉 Clinical Trials (5)Relevance: 72%

0
Active

0
Completed

554
Total Enrolled

PHASE2
Highest Phase

Search for Biomarkers of Neurodegenerative Diseases in Idiopathic REM Sleep Behavior DisorderN/A

UNKNOWN·NCT04048603 · Chinese University of Hong Kong

182 enrolled · 2019-05-15 · → 2022-03-31

This study is a prospective study with a mean of 7-year follow-up interval, aims to monitor the progression of α-synucleinopathy neurodegeneration by the evolution of prodromal markers and development

REM Sleep Behavior Disorder Neurodegeneration

Efficacy of Dorzolamide as an Adjuvant After Focal Photocoagulation in Clinically Significant Macular EdemaN/A

UNKNOWN·NCT02227745 · Hospital Juarez de Mexico

60 enrolled · 2014-01 · → 2015-03

Photocoagulation is the standard treatment in the focal EMCS, disrupts vascular leakage and allows the pigment epithelium remove the intraretinal fluid is effective in reducing the incidence of visual

Diabetic Retinopathy Diabetic Macular Edema

Dorzolamide hydrochloride (2%) Placebo Sodium hyaluronate 4mg

Evaluation of the Frequency and Severity of Sleep Abnormalities in Patients With Parkinson's DiseaseNA

UNKNOWN·NCT04387812 · Tel-Aviv Sourasky Medical Center

240 enrolled · 2020-06-01 · → 2023-12-31

Sleep disturbances are one of the most common non-motor symptoms in PD, with an estimated prevalence as high as 40-90%. Sleep disturbances (particularly sleep duration, sleep fragmentation, Rapid Eye

Parkinson Disease GBA Gene Mutation Leucine-rich Repeat Kinase 2 (LRRK2) Gene Mutation

Xtrodes home PSG system

Ambroxol in Disease Modification in Parkinson DiseasePHASE2

COMPLETED·NCT02941822 · University College, London

23 enrolled · 2016-12 · → 2018-04

This study will evaluate the safety, tolerability and pharmacodynamics of ambroxol in participants with Parkinson Disease. Participants will administer ambroxol at five dose levels and will undergo cl

Parkinson Disease

Ambroxol

Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 ParkinsonismPHASE2

COMPLETED·NCT01759888 · Chang Gung Memorial Hospital

49 enrolled · 2011-08 · → 2014-12

The primary objective of this protocol is to access the utility of 18F-DTBZ PET imaging as an in vivo biomarker to monitor neurodegeneration of both PD mouse models and PD patients. Secondary, the inv

Parkinson's Disease

18F-DTBZ

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for MAPK14 →

No DepMap CRISPR Chronos data found for MAPK14.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

8.0 years

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend

↘

Falling

7d Momentum

▼ 3.5%

Volatility

Medium

0.0205

Events (7d)

6

Price History

▼27.6%

💾 Resource Usage

LLM Tokens

7,790

$0.0234

Total Cost

$0.0234

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
Combined p38α inhibition and PRMT1 activation will shift TDP-43 toward a hypermethylated/hypophosphorylated state in TDP-43opathy cellular models, achieving at least 40% increase in symmetric dimethyl	TDP-43 methylation:phosphorylation ratio increases by ≥40% (measured by quantitative immunoblotting of methylated vs. phosphorylated TDP-43), with concurrent re	— no observation —	pending	0.62
In a TDP-43 transgenic mouse model (TDP-43 A315T), combined p38α inhibitor treatment at sub-inflammatory doses (1-2 mg/kg) plus PRMT1 indirect activation will delay motor impairment onset by ≥25% and	Primary endpoint: latency to fall on rotarod decreases by ≥25% slower progression (log-rank p < 0.05); secondary: survival extends by median 15 days (95% CI: 8-	— no observation —	pending	0.55

🔮 Falsifiable Predictions (2)

pendingconf 62%

Combined p38α inhibition and PRMT1 activation will shift TDP-43 toward a hypermethylated/hypophosphorylated state in TDP-43opathy cellular models, achieving at least 40% increase in symmetric dimethylarginine modification at the expense of phospho-S409/410 site occupancy.

Predicted outcome: TDP-43 methylation:phosphorylation ratio increases by ≥40% (measured by quantitative immunoblotting of methylated vs. phosphorylated TDP-43), with con

Falsification: If PRMT1 activation (via CRISPR activation or chemical inducer) fails to increase TDP-43 methylation by ≥30% within 48 hours, OR if combined treatment produces no statistically significant improvement

pendingconf 55%

In a TDP-43 transgenic mouse model (TDP-43 A315T), combined p38α inhibitor treatment at sub-inflammatory doses (1-2 mg/kg) plus PRMT1 indirect activation will delay motor impairment onset by ≥25% and extend survival by ≥15 days compared to vehicle-treated controls.

Predicted outcome: Primary endpoint: latency to fall on rotarod decreases by ≥25% slower progression (log-rank p < 0.05); secondary: survival extends by median 15 days (

Falsification: If combined treatment fails to delay motor impairment onset by at least 15% OR extend median survival by less than 10 days compared to either monotherapy arm (p > 0.05 for log-rank test), OR if surviv

📖 References (4)

Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration.
Kellett EA et al.. Molecular neurodegeneration (2025)
PubMed↗DOI↗
Opposing roles of p38α-mediated phosphorylation and PRMT1-mediated arginine methylation in driving TDP-43 proteinopathy.
Aikio M et al.. Cell Rep (2025)
PubMed↗DOI↗
Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death.
["Gasset-Rosa Fatima" et al.. Neuron (2019)
PubMed↗DOI↗
Calcium-dependent methylation by PRMT1 promotes erythroid differentiation through the p38α MAPK pathway.
Liu MY et al.. FEBS Lett (2020)
PubMed↗DOI↗

▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate

source	v1_phase_c_backfill
origin_type	gap_debate
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

0%

Debates

0

Incoming

0

Outgoing

0

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

Composite		89%
Mech.		75%
Evidence		72%
Novelty		65%
Feasibility		78%
Impact		82%
Druggability		68%
Safety		60%
Competition		70%
Data avail.		75%
Reproducibility		70%

📗 Cite This Artifact

p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphorylation-Methylation Balance

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — MAPK14

💉 Clinical Trials (5)Relevance: 72%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🔮 Predictions

📖 References (4)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion

📗 Cite This Artifact

p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphorylation-Methylation Balance

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — MAPK14

💉 Clinical Trials (5)Relevance: 72%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🧭 Related

associated with (1)

causal extracted (1)

causes (4)

co discussed (2)

inhibits (2)

modulates (3)

prevents (1)

promoted: p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphorylation-Methy (1)

regulates (1)

🔮 Predictions

📖 References (4)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion